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Fungal infections, ranging from superficial to life-threatening infections, represent a major public 
health problem that affects 25% of the worldwide population. In this context, the study of host-
pathogen interactions within the host is crucial to advance antifungal therapy. However, since fungal 
cells are usually outnumbered by host cells, the fungal transcriptome frequently remains uncovered. 
We compared three different methods to selectively lyse human cells from in vitro mixes, composed of 
Candida cells and peripheral blood mononuclear cells. In order to prevent transcriptional modification, 
the mixes were stored in RNAlater. We evaluated the enrichment of fungal cells through cell counting 
using microscopy and aimed to further enrich fungal nucleic acids by centrifugation and by reducing 
contaminant nucleic acids from the host. We verified the enrichment of fungal DNA and RNA through 
qPCR and RT-qPCR respectively and confirmed that the resulting RNA has high integrity scores, suitable 
for downstream applications. The enrichment method provided here, i.e., lysis with Buffer RLT followed 
by centrifugation, may contribute to increase the proportion of nucleic acids from fungi in clinical 
samples, thus promoting more comprehensive analysis of fungal transcriptional profiles. Although we 
focused on C. albicans, the enrichment may be applicable to other fungal pathogens.
Superficial fungal infections represent a major public health problem worldwide, affecting 25% of the population. 
These infections are caused mainly by several species of dermatophytes of which Trichophyton rubrum is the 
most common1. Though superficial fungal infections are rarely life-threatening, they generally require very long 
and tedious antifungal treatments2. Mucosal infections such as vulvovaginal candidiasis are also very common, 
affecting millions of women every year. In fact, it is the second most common type of vaginal infection after bac-
terial vaginosis3. This infection develops into recurrent vulvovaginal candidiasis in many patients (5–8%) which 
impacts directly on their social lives and can be fatal in immunocompromised individuals4,5. Systemic, severe and 
life-threatening fungal infections, have also a significant impact on public health with cryptococcosis, aspergil-
losis and candidiasis as main diseases, with candidiasis as the most common of them6. They have a high rate of 
mortality, reaching 46% in candidaemia cases in Europe7. Candidiasis is mainly caused by C. albicans, although 
other Candida species have emerged during the last years, such as C. glabrata, C. parapsilosis and C. tropicalis, and 
very recently the multidrug-resistant pathogen C. auris has been involved in several outbreaks8,9.
Given the clinical relevance of fungal infections, there have been efforts to elucidate host-pathogen interac-
tions in recent years, involving candidiasis10–12, aspergillosis13–16 and cryptococcosis17,18. However, most of these 
studies were focused on the transcriptome of the host. Transcriptomic studies which identify comprehensively 
differently expressed genes from the fungus are predominantly limited to in vitro experiments in which cells are 
cultured19 or animal models infected with a high inoculum of the pathogen20, which is usually not representative 
for the low amount of fungal cells encountered in the host. Although in vitro experiments contribute to improve 
our knowledge regarding the mechanisms of fungal pathogenicity and the immune response of the host, they 
reflect within-host interactions only to a limited extent, because these are further influenced by signalling path-
way networks involving different metabolites, cell types and other microorganisms that are present in the ecosys-
tem of the host. The use of a high burden of the pathogen in animal studies counterbalances the proportion of the 
fungus that is present in clinical samples. In fact, RNA content from the fungal pathogen was recently found to 
constitute only about 0.1% of total RNA21. Therefore, for true host-pathogen interaction studies, carried out on 
clinical samples, there is a need to enrich fungal RNA to obtain a more comprehensive analysis of transcriptional 
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profiles from the pathogen side. To our knowledge, there are only three studies that have attempted to solve this 
question and developed different enrichment methods. Amorim-Vaz et al.21 used a large set of Candida-specific 
probes to selectively enrich fungal mRNAs, in combination with subsequent RNA-seq, Andes et al.22 developed 
a simple approach to enrich fungal RNA through the lysis of human cells with Triton X-100 and Hebecker et al.23 
used buffer RLT (Qiagen) with a homogenizer to lyse murine cells, although none of these studies started from 
RNAlater.
In this paper, we compared three different methods to enrich fungal nucleic acids from in vitro mixes com-
posed of different amounts of Candida cells and peripheral blood mononuclear cells (PBMCs) that had been 
stored in RNAlater in order to halt transcription. We evaluated the efficiency of the enrichment through cell 
counting, quantitative PCR (qPCR) and quantitative reverse transcription PCR (RT-qPCR). Finally, we checked 
RNA quality of fungal RNA obtained after the enrichment.
Results
Brief outline of the study. Figure 1 summarizes the plan of the study. Three different methods to enrich 
fungal cells and further enrich nucleic acids from pathogenic fungi were compared. First, we prepared aliquots 
of mixes composed of 106 yeast cells/ml and 106 PBMCs/ml, and stored these mixtures in aliquots of 1 ml in 
RNAlater at −80 °C.
For the three different lysis treatments, we determined the number of yeast cells and PBMCs that survived the 
treatment by means of microscopy.
Subsequently, we also investigated whether fungal nucleic acids could be further enriched by centrifugation to 
precipitate intact yeast cells and to reduce human DNA and RNA from the lysed PBMCs, and we quantified DNA 
and RNA by qPCR and RT-qPCR respectively, and analysed RNA integrity with a Fragment Analyzer.
Finally, we determined the efficacy of these enrichment procedures for mixtures containing yeast cells reduced 
10- and 100-fold relative to the human counterpart.
Enrichment of fungal cells through lysis of human cells. Unlike fungal cells, human cells do not have 
a protective cell wall to deal with adverse conditions. This distinction can be used to enrich fungal cells through 
the differential lysis of human cells, which can potentially constitute the first step to enrich nucleic acids from the 
pathogenic fungus in a clinical sample. Here, we tested the effect of three different methods, all at room temper-
ature, to lyse human cells: i) chemically with Triton X-100 for 20 min and ii) with Buffer RLT supplemented with 
1% β-mercaptoethanol (i.e., 143 mM) for at least 1 min (in house protocol), and iii) mechanically by bead beating 
with 0.5 mm zirconium beads in saline for 10 min. Results are depicted in Fig. 2. Using microscopy, we observed 
that the number of yeast cells remained invariable among all three methods considered in the study.
For PBMCs, we observed that Buffer RLT completely lysed human cells (0 cells/ml) and that bead beat-
ing lysed most of them (5.3 × 104 residual cells/ml). This reduction was significant as compared to the control 
(9.4 × 105 cells/ml) (p < 0.05) and in addition, the differences between Buffer RLT and bead beating were sig-
nificant as well. Triton X-100 did not effectively lyse human cells (4.9 × 105 residual cells/ml). Thus, these results 
indicate that Buffer RLT and bead beating selectively lyse human cells and therefore, these methods can be used 
to enrich fungal cells after RNAlater storage.
Nucleic acids extraction
RiboPure Yeast Kit
Degradation of human cells (PBMCs)
Centrifugation to pellet fungal cells
20 000 g for 8 min 
Mixtures of 104, 105 or 106 yeast cells and 106 PBMCs per ml
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qPCR
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Figure 1. A schematic overview of the study set up.
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Treatment with Buffer RLT is the most efficient method to enrich fungal DNA. As we observed 
that Buffer RLT and bead beating in saline did reduce the number of human cells, while not affecting the number 
of yeast cells, we next questioned whether DNA from the fungal pathogen would be enriched as well. For this 
purpose, the mixes were treated with the three methods of cell lysis mentioned above, but followed by a centrifu-
gation step (20 000 g, 8 min, room temperature), aiming at concentrating fungal cells and reducing nucleic acids 
and cell debris from human cells.
qPCR results of nucleic acids extracted with the RiboPure Yeast Kit are shown in Table 1 (human DNA 
and fungal DNA), targeting CXCL1 (human gene) and the internal transcribed spacer region 1 (ITS-1) DNA 
(yeast gene), respectively. Treatment with Buffer RLT followed by centrifugation induced a significant reduction 
of human DNA (p < 0.05), resulting in a Cq value of 35.9 which corresponds to only 0.09% human DNA as 
compared to the control (Cq value of 25.3) (Table 1). Enrichment with bead beating also reduced significantly 
human DNA (Cq value of 27.8) but a paired samples t-test showed that Buffer RLT is significantly more efficient 
(p < 0.001). Triton X-100 reduced human DNA to 63.8% (Cq value of 26.0), but this was not statistically sig-
nificant. Additional incorporation of a DNase treatment to remove contaminating human DNA from samples 
treated with Buffer RLT did not further improve the enrichment, as Cq values of 36.21 and 36.50 were obtained 
before and after DNase treatment (see Supplementary Table S1). In addition, Table 1 shows that fungal DNA was 
not affected by any of the enrichment methods considered in this study. We concluded that bead beating and 
Figure 2. Number of yeast cells and PBMCs per ml determined by a haemocytometer, at magnification of 
400x, after different cell lysis methods. Error bars represent the standard deviations of results from six biological 
replicates. Statistically significant differences are marked with one (p < 0.05) or two (p < 0.005) asterisks 
(Friedman test) and with one bracketed asterisk (p < 0.05) (Wilcoxon test).
Human DNA Cq valueb SD Log cells/mlc CV DNA %c CV
No enrichment 25.31 0.46 5.99 0.02 100.00 0.26
Buffer RLT 35.89** 0.59 2.96 0.06 0.09 0.32
Triton X-100 26.00 0.28 5.79 0.01 63.82 0.17
Bead beating 27.84* 1.62 5.27 0.09 18.93 0.66
Fungal DNA Cq value SD Log cells/mlc CV DNA %c CV
No enrichment 23.20 0.22 6.05 0.01 100.00 0.13
Buffer RLT 23.50 0.47 5.97 0.02 83.08 0.25
Triton X-100 23.87 0.66 5.87 0.03 66.03 0.34
Bead beating 23.60 1.62 5.94 0.07 77.91 0.63
Human RNA Cq valueb SD Log cells/mlc CV RNA %c CV
No enrichment 30.17 0.37 6.13 0.02 100.00 0.20
Buffer RLT 35.00** 0.61 4.85 0.03 5.20 0.31
Triton X-100 34.53** 0.60 4.98 0.03 6.93 0.31
Bead beating 34.25** 1.05 5.05 0.06 8.20 0.48
Fungal RNA Cq valueb SD Log cells/mlc CV RNA %c CV
No enrichment 20.25 0.48 5.93 0.03 100.00 0.29
Buffer RLT 20.97 0.22 5.71 0.01 59.94 0.14
Triton X-100 37.70** 0.77 0.52 0.46 0.00 0.42
Bead beating 34.02** 0.82 1.66 0.15 0.01 0.44
Table 1. Effect of different enrichment methods on PCR-based amplificationa of human DNA, fungal DNA, 
human RNA and fungal RNA. aHuman nucleic acids amplified with CXCL-1 primers and fungal nucleic 
acids amplified with ITS-1 primers. bCq values are means of six biological replicates composed of mixes of 
106 PBMCs and 106 Candida cells. Statistically significant differences are marked with one (p < 0.005) or two 
asterisks (p < 0.001) (Linear mixed model). cLog cells/ml, DNA percentage and RNA percentage were calculated 
by extrapolation of Cq values with a standard curve. SD: Standard deviation. CV: Coefficient of variation.
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treatment with Buffer RLT enriched fungal cells as well as fungal DNA, by reducing the human DNA content of 
the mixes, with Buffer RLT treatment being the most efficient method.
Treatment with Buffer RLT additionally enriches fungal RNA. After testing the enrichment of cells 
and of DNA from the pathogenic fungus with three different methods, and with the addition of a centrifugation 
step, we evaluated whether RNA was also enriched together with DNA. Therefore, the nucleic acids obtained 
from the differently treated mixes after extraction by means of the RiboPure Yeast Kit, were further treated with 
DNase to obtain pure RNA, and quantitative reverse transcription PCR (RT-qPCR) was carried out. We observed 
that treatment with Buffer RLT, Triton X-100 and bead beating resulted in very low amounts of human RNA, i.e. 
5.2, 6.9 and 8.2% respectively (Table 1). Double enzymatic pretreatment prior to the lysis of fungal cells, first with 
DNase and subsequently with RNase, to remove remaining human nucleic acids, did not further improve the 
RNA enrichment (Supplementary Table S1). Furthermore, Table 1 shows no significant differences between treat-
ment with Buffer RLT and the untreated control for fungal ITS-1 RNA, whereas fungal RNA drastically decreased 
with both bead beating and Triton X-100 treatment, i.e. no residual RNA and 0.01% residual RNA, respectively, 
indicating that not only human but also fungal RNA was lost. These results suggest that only treatment with 
Buffer RLT can be used to enrich fungal RNA.
Enrichment with Buffer RLT in 1:10 and 1:100 ratios. After having shown that Buffer RLT enrichment 
can be used to enrich nucleic acids from the fungal pathogen in samples with equal numbers of fungal and human 
cells, through the lysis of human cells, the enrichment procedure was tested in Candida/PBMC ratios of 1:10 and 
1:100. To this purpose, we prepared mixtures of 105 Candida cells/106 PBMCs per ml and 104 Candida cells/106 
PMBCs per ml. Cq values after qPCR of nucleic acids extracts for human and fungal DNA and after RT-qPCR 
of human and fungal RNA are shown in Table 2. DNA from human cells was significantly reduced to 0.65% and 
0.67% of the initial number of cells (p < 0.05) for the 105 and 104 yeast cells/ml mixtures, respectively, while DNA 
from yeasts was (not significantly) reduced to 68.6% and 53.1%. Accordingly, human RNA significantly dropped 
to 4.9% and 9.3% (p < 0.05), while fungal cDNA was not significantly reduced to 61.5% and 34.7% for the 105 and 
Human DNA Cq valueb SD Log cells/mlc CV DNA %c CV
106 PBMCs + 105 Candida cells
No enrichment 24.39 0.67 6.08 0.03 100.00 0.34
Buffer RLT 32.52* 0.55 3.89 0.04 0.65 0.29
106 PBMCs + 104 Candida cells
No enrichment 24.87 0.13 5.95 0.01 100.00 0.08
Buffer RLT 32.95* 0.65 3.77 0.05 0.67 0.33
Fungal DNA Cq valueb SD Log cells/mlc CV DNA %c CV
106 PBMCs + 105 Candida cells
No enrichment 23.74 0.59 5.02 0.03 100.00 0.32
Buffer RLT 24.31 0.58 4.85 0.03 68.56 0.32
106 PBMCs + 104 Candida cells
No enrichment 27.77 0.10 3.85 0.01 100.00 0.07
Buffer RLT 28.72 0.25 3.57 0.07 53.05 0.45
Human RNA Cq valueb SD Log cells/mlc CV RNA %c CV
106 PBMCs + 105 Candida cells
No enrichment 30.65 0.88 6.09 0.04 100.00 0.45
Buffer RLT 35.15* 0.98 4.78 0.06 4.91 0.48
106 PBMCs + 104 Candida cells
No enrichment 30.74 1.65 4.37 0.10 100.00 0.64
Buffer RLT 34.57* 0.71 3.34 0.06 9.30 0.36
Fungal RNA Cq valueb SD Log cells/mlc CV RNA %c CV
106 PBMCs + 105 Candida cells
No enrichment 22.51 0.52 5.06 0.03 100.00 0.28
Buffer RLT 23.26 0.46 4.84 0.03 61.47 0.26
106 PBMCs + 104 Candida cells
No enrichment 25.47 0.54 4.22 0.04 100.00 0.30
Buffer RLT 27.10 0.82 3.76 0.06 34.69 0.41
Table 2. Effect of Buffer RLT treatment on DNA and RNA enrichment from yeast cells for mixtures composed 
of different ratios of PBMCs and Candida cells, as determined by qPCR-based amplificationa of human DNA 
and fungal DNA, and by RT-qPCR based amplificationa of human RNA and fungal RNA. aHuman nucleic acids 
amplified with CXCL-1 primers and fungal nucleic acids amplified with ITS-1 primers. bCq values are means 
of six biological replicates. Statistically significant differences are marked with one asterisk (p < 0.05) (paired-
samples Wilcoxon test). cLog cells/ml, DNA percentage and RNA percentage were calculated by extrapolation of 
Cq values with a standard curve. SD: Standard deviation. CV: Coefficient of variation.
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104 yeast cells/ml mixtures. Together, these results demonstrate that enrichment with Buffer RLT enriches fungal 
nucleic acids from mixtures with human cells, also in cases when low proportions of fungal cells are present.
RNA quality is suitable for transcriptomic analysis. Obtaining high quality RNA is essential to per-
form comprehensive and reliable transcriptomic analyses. After having shown that enrichment with Buffer 
RLT is an efficient method to enrich both DNA and RNA from the pathogen fungus from mixes with 10- to 
100-fold more human cells. We analysed RNA integrity to check to what extent it can be used for high-quality 
RNA-demanding experiments such as RNA-seq. Electropherograms of some RNA samples enriched with differ-
ent methods are shown in Fig. 3. RQN values were around 10 for Buffer RLT enrichment and no degradation was 
detected. Contrarily, Triton X-100 and bead beating enrichments resulted in poor electropherogram profiles with 
evident RNA degradation. We concluded that enrichment with Buffer RLT confers high-quality RNA which can 
be used in transcriptomic analysis.
Discussion
Host-pathogen interactions in vivo are frequently hampered by the low proportion of microbial cells as com-
pared to host cells, resulting in poor transcriptional profiles from the pathogen side. In this study, we approached 
this problem by comparing different methods to selectively lyse human cells in order to increase the proportion 
of fungal cells. This enrichment of fungal cells through differential cell lysis was further complemented with 
centrifugation to decrease contaminant cell debris and nucleic acids of the human host cells. In our study, we 
started from mixtures containing 106 Candida cells and 106 PBMCs, that had been stored in RNAlater, a solution 
that has been shown to be as efficient as snap-frozen methods to keep transcriptomic profiles unmodified24. Its 
use is increasing during recent years because it allows short-term storage of clinical samples at above-freezing 
Figure 3. RNA integrity of some RNA samples after enrichment with buffer RLT, Triton X-100 and bead 
beating. Electropherogram profiles were determined with a Fragment Analyzer. Quality for Fragment Analyzer 
is shown as the RQN value. Reported on a scale of 1 to 10, with higher values indicating a better quality of total 
RNA. Values above 7 are considered to represent high quality and non-degraded RNA.
6Scientific RepoRtS |         (2019) 9:18037  | https://doi.org/10.1038/s41598-019-54608-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
temperatures for RNA extraction purposes. This is especially relevant in clinical settings in which samples cannot 
be frozen immediately in liquid nitrogen.
The methods compared for differential cell lysis were Buffer RLT treatment, Triton X-100 incubation and bead 
beating in saline.
Triton X-100 is a non-ionic surfactant widely used to lyse different types of human cells such as red blood 
cells25, monocytes26 and dendritic cells27.
Bead beating has also been used extensively to lyse different microorganisms including bacteria28,29 and 
fungi30,31 and less often human cells32. Although bead beating is usually applied in combination with a lysis buffer, 
we used saline instead to avoid lysis of yeast cells.
Although Buffer RLT is a commercial lysis buffer which has been used in different protocols and kits for the 
lysis of cells and tissues prior to RNA extraction33–35, its effectiveness as a differential lysis buffer for human and 
fungal cells has not been studied yet.
Cell lysis was previously determined indirectly by quantification of released haemoglobin25, of released LDH26 
and of metabolic activity and efficiency of protein extraction27. Here, we used microscopy and cell counting to 
directly quantify the number and type of cells that were lysed. We found that yeast cells were resistant to all three 
lysis methods, as we had expected, since i) the fungal cell wall confers protection against different stress condi-
tions36, ii) the cell mixtures had been stored in RNAlater, which makes cells harder to lyse37, and iii) a combina-
tion of both bead beating and an efficient lysis buffer is needed to effectively lyse Candida cells37. We found that 
Buffer RLT was the most efficient method to lyse human cells. In addition, Buffer RLT was also the fastest method, 
since pipetting up and down several times was sufficient to lyse 100% of human cells, while Triton X-100 and bead 
beating required protocols lasting for 20 and 10 min respectively.
The reduced effectiveness in lysis of the PBMCs (<100%) that we obtained with Triton X-100 and bead beat-
ing in saline is probably due to the pre-storage in RNAlater, since Triton X-100 is a well-known detergent widely 
used in cell lysis but its use for samples stored in RNAlater has not been evaluated previously. In fact, there are 
no studies analysing the efficiency of cell lysis in samples stored in RNAlater apart from our recent study with C. 
albicans37. Buffer RLT is a more powerful chemical agent (chaotropic) that is not affected by RNAlater.
In addition, using qPCR and RT-qPCR, we demonstrated that after cell lysis with Buffer RLT, both fungal 
DNA and RNA can be further enriched by means of a centrifugation step that effectively reduced human nucleic 
acids. However, we observed that pellets of fungal cells were not strongly attached at the bottom of the tube, which 
may be due to the presence of large amounts of (human) DNA in the supernatant, which may increase viscosity, 
and interfere with the centrifugation process. Therefore, care should be taken at removal of the supernatants, to 
avoid removal of the pellet. For this reason, we also recommend to not include more than three samples per run 
of centrifugation. Using the enrichment with Buffer RLT and centrifugation, only 0.1% human RNA and 5.2% 
human DNA were left, which represents an important reduction of (human) nucleic acids. In a further effort to 
completely remove contaminating human nucleic acids, we also added DNase and RNase digestion after Buffer 
RLT treatment and centrifugation prior to RNA extraction. Andes et al.23, who also used Triton X-100 to enrich 
fungal cells, had shown that RNase digestion not only decreased human GADPH mRNA, but surprisingly also 
increased fungal actin mRNA, according to RT-qPCR. However, we did not succeed to reduce human RNA with 
Triton X-100, and enzymatic digestion did not further increase fungal RNA. Our contradictory results can be 
explained by the influence of RNAlater which can impair cell lysis and enzymatic treatments.
Using Buffer RLT treatment, followed by centrifugation, fungal DNA and RNA were reduced to - statistically 
non-significant - 83.1% and 59.9% of the original amount present, as assessed by qPCR and RT-qPCR. In sum-
mary, the Buffer RLT enrichment in combination with centrifugation was most efficient to reduce human RNA 
and can be performed in less than 10 min, further reducing the risk of unwanted transcriptomic profile changes.
Furthermore, we simulated the low proportion of fungal cells that is encountered in the host during colonisation 
or infection by reducing the number of fungal cells 10- and 100-fold relative to the number of human cells. This strat-
egy has been used in other in vitro experiments38–40, and gives a better approximation of host-pathogen ratios present 
in vivo. It should be noted that many in vitro studies used a number of pathogen cells higher than that of the host 
cells, most likely, in order to, for example, increase the signal of luminescence during ROS production assays41, to 
increase the signal obtained during chromatographic analyses to study metabolite profiles42 or to stimulate a stronger 
immune response43,44. Most importantly, we obtained similar results to our experiments when using a 1:1 ratio.
Although we aimed to mimic the in vivo situation by mixing PBMCs and yeast cells in different ratios, a limi-
tation of our study may be that these mixtures did not reflect possible interactions which may occur in vivo, such 
as PBMC stimulation, lysis, invasion of human cells by yeast cells or adherence between human and yeast cells.
Finally, we obtained high-quality RNA after Buffer RLT enrichment, as assessed with Fragment Analyzer, 
demonstrating that RNA integrity was not compromised during the enrichment process. This facilitates RNA-seq 
experiments and any other downstream application.
Apart from RNA, we also enriched DNA. Although we did not analyse DNA quality, we assume that Buffer 
RLT enrichment may be used for genomic studies as well, since DNA is more stable than RNA. Indeed, also 
genomic studies have to cope with the overwhelming amount of host DNA contamination in clinical samples. 
For example, a recent study reported about the need of DNA enrichment in metagenomic studies of sputum, and 
described a microbe enrichment microfluidic device coupled with DNA amplification45. However, although this 
enrichment is suitable for different bacteria, fungi are not so well recovered because of their larger size.
The enrichment method described here is based on the selective lysis of human cells, taking advantage of the 
protective properties that the cell wall confers to fungal cells. A comparable protocol has been published using 
RNAPure instead of Buffer RLT, but without explicitly showing the efficiency46. Andes et al.23 also enriched fungal 
RNA through the lysis of human cells. However, their protocol requires two incubations during 20 min at 37 °C 
and as such gene expression prior to RNA extraction may be changed, which would no longer match the expres-
sion profile encountered during the infection. Another study used 55.000 Candida-specific probes to match every 
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gene and splicing variant of the fungal transcriptome22. As such, these authors carried out an enrichment after 
and not prior to RNA extraction. This gives an important advantage since transcriptomic profiles may change 
during the enrichment process. However, disadvantages of this method include certain cross-hybridization that 
is inherent to the technique and the cost of the probes. Using RNA-seq in two animal models, they obtained from 
0.03% to 0.1% of reads aligned to C. albicans before the enrichment, and fungal reads were enriched to 58–69% 
with the probes. Since they do not provide how many of the 31–42% of unmapped reads were mapped as human, 
the provenance of these reads is unknown.
In summary, the clinical relevance of fungal infections has boosted the interest in host-pathogen interactions. 
Expanding our knowledge in this field will contribute to develop new diagnostic tools, identify potential vaccine 
candidates and improve the antifungal treatments we have used for more than 30 years and that are becoming 
increasingly obsolete47. The enrichment described here may enable more comprehensive analyses of transcrip-
tional profiles from fungal pathogens within the host. Furthermore, we should evaluate whether this approach is 
also applicable for dermatophytes, whose cell walls are even tougher than Candida.
Methods
Culture of Candida albicans. Candida albicans reference strain ATCC 90028 was grown on Sabouraud 
Glucose Agar plates with Chloramphenicol (50 μg/ml) and transferred to Yeast extract - Peptone Dextrose broth. 
Cell suspensions were subcultured at 32 °C in static conditions overnight until the logarithmic growth phase was 
reached. Cells were counted with a microscope by using a haemocytometer (Bürker chamber). Cell suspensions 
were adjusted with the same broth to 2 × 106, 2 × 105 and 2 × 104 cells/ml and centrifuged at 8000 g for 10 min, 
whereafter pellets were resuspended in 1-ml aliquots in RNAlater (Invitrogen, Carlsbad, CA) and placed at 4 °C 
following immediate preparation of yeast cells/PBMCs mixtures.
PBMC isolation. PBMCs were isolated from a buffycoat as described previously48 after informed consent 
from all participants. Cell pellets were resuspended in RNAlater to a concentration of 2 × 106 cells/ml and divided 
into 1-ml aliquots and placed at 4 °C following immediate preparation of yeast cells/PBMCs mixtures. We confirm 
that all methods were carried out in accordance to relevant guidelines and regulations and that all experimental 
protocols were approved by the ethical committee of the University of Ghent (EC/2016/0192).
Preparation of yeast cells/PBMCs mixtures and RNAlater treatment. Volumes of 500 µl of 1 
ml-aliquots containing 2 × 106, 2 × 105 and 2 × 104 yeast cells/ml and 500 µl of 1 ml-aliquots with 2 × 106 PBMCs/
ml were mixed together to obtain 1-ml aliquots of 106:106, 105:106 and 104:106 yeasts cells:PBMCs mixtures. These 
mixtures were stored overnight at 4 °C to enable the RNAlater to penetrate into the cells, and subsequently stored 
at −80 °C.
Cell lysis of human cells. Mixtures of yeast cells and PBMCs that had been stored at −80 °C, were thawed, 
centrifuged for 10 min at 20 000 g and resuspended in 1-ml aliquots of i) Triton X-100 (final concentration, 1%), ii) 
Buffer RLT (Qiagen, Hilden, Germany) supplemented with 1% β-mercaptoethanol and iii) saline. Buffer RLT and 
Triton X-100 samples were incubated for at least 1 min and 20 min respectively, while saline samples were transferred 
to prefilled tubes with 0.5 mm zirconium beads and further bead beaten for 10 min in a hands-free vortex genie-2 
(MO BIO Laboratories, Carlsbad, CA), fitted with a vortex adapter that allows bead beating in a horizontal position.
Microscopic visualization and cell viability determination. After the different cell lysis treatments, cell 
suspensions were centrifuged for 10 min at 8000 g to collect intact yeast cells and PBMCs. They were then resus-
pended in 1 ml of saline prior to cell counting with a microscope. Ten µl of this saline cell suspension was loaded 
into a haemocytometer. Yeast cells and PBMCs could be observed with light microscopy and were counted in 25 
small squares with 0.2 mm sides (together representing a 0.1 µl volume) at a magnification of 400x. The resulting 
number of cells/ml was calculated as follows: cells/ml = cell number (in 25 small squares) × 1 (dilution) × 104.
Centrifugation conditions for enrichment. Centrifugation at 20 000 g for 8 min at room temperature 
was used to pellet fungal cells. Supernatants containing cell debris from human cells that had been lysed with 
the three different methods were discarded very carefully, since fungal pellets were very loose and they can be 
detached very quickly. No more than three samples were centrifuged per run of centrifugation to minimize the 
risk of fungal pellets being removed together with cell debris from human cells.
DNase and RNase treatment. Pellets of intact yeast cells were treated to digest contaminating human 
DNA and RNA. First, pellets were resuspended in 86 µl nuclease-free water, and DNase treatment was performed 
by addition of 10 µl of 10x DNase I buffer and 4 µl of DNase I (2 U/µl) and by incubation for 30 min at 37 °C. 
Second, the yeast pellet was processed for RNase treatment by addition of 98 µl of nuclease-free water and 2 µl of 
RNase A Solution (4 mg/ml). The mixture was then incubated for 1 h at 37 °C.
Nucleic acids extraction. Nucleic acids were isolated using the RiboPure Yeast Kit (Invitrogen) and fol-
lowing the manufacturer’s instruction of the kit. Half of the resulting nucleic acids was used directly for DNA 
quantification by means of qPCR, and the other half was treated with DNase I to obtain pure RNA. RNA was then 
analyzed for quality with a NanoDrop spectrophotometer and a Fragment Analyzer (DNF-472 High-Sensitivity 
Total RNA, Applied Biosystems) and subsequently quantified with RT-qPCR.
qPCR and RT-qPCR analysis. Reverse transcription was performed for 5 min at 25 °C followed by 60 min at 
42 °C with random hexamer primers and with 5 µl of total RNA according to the instructions of the manufacturer 
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of the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA). qPCR from both 
cDNA and DNA was performed in duplicate with a LightCycler 480 (Roche). We used CXCL1_F forward 
(5′-GGA AAG AGA GAC ACA GCT GCA-3′) and CXCL1_R reverse (5′-AGA AGA CTT CTC CTA AGC GAT 
GC-3′) primers, previously described (Van Belleghem et al.48), targeting the human gene encoding the cytokine 
CXCL1, and CA_rRNA F (5′-TTT GCT TGA AAG ACG GTA-3′) and CA_rRNA R (5′-TTG AAG ATA TAC 
GTG GTG G-3′) targeting the ITS-1 gene of C. albicans (adapted from49). PCR master mixes to quantify both 
human cDNA/DNA and yeast cDNA/DNA were prepared similarly, i.e. Roche LC480 high resolution melting 
(HRM) mix (Roche, Basel, Switzerland), 0.5 µM primers and 2 µl sample (cDNA or DNA) in a final volume of 
10 µl, with exception of MgCl2 which was used at a concentration of 2 mM and 3 mM to amplify human cDNA/
DNA and yeast cDNA/DNA respectively. The thermal cycling program consisted of a pre-incubation step for 
10 min at 95 °C, amplification for 45 cycles of 30 s at 95 °C, 30 s at 59 °C and 30 s at 72 °C. Results were analyzed 
with the LightCycler 480 software 1.5 (Roche).
Statistical analysis. For statistical comparisons of cell lysis and PCR data (cq values), independent exper-
iments performed with six replicates were considered. Data were analyzed using the linear mixed model for 
repeated measures followed by Bonferroni’s multiple testing correction, and with Friedman’s test and Wilcoxon’s 
test where the assumption of normality was not acceptable, using the IBM SPSS Statistics software v 25.0 (IBM, 
Armonk, NY, USA).
Data availability
The datasets used and analysed during the current study are available from the corresponding author on 
reasonable request.
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